Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease

We have compared the efficacy of two Leishmania (Leishmania) major vaccines, one genetically attenuated (DHFR-TS deficient organisms), the other inactivated [autoclaved promastigotes (ALM) with bacillus Calmete-Guérin (BCG)], in protecting rhesus macaques (Macaca mulatta) against infection with virulent L. (L.) major. Positive antigen-specific recall proliferative response was observed in vaccinees (79% in attenuated parasite-vaccinated monkeys, versus 75% in ALM-plus-BCG-vaccinated animals), although none of these animals exhibited either augmented in vitro gamma interferon (IFN-<FONT FACE=Symbol>g</font>) production or positive delayed-type hypersensitivity (DTH) response to the leishmanin skin test prior to the challenge. Following challenge, there were significant differences in blastogenic responses (p < 0.05) between attenuated-vaccinated monkeys and naïve controls. In both vaccinated groups very low levels of antibody were found before challenge, which increased after infective challenge. Protective immunity did not follow vaccination, in that monkeys exhibited skin lesion at the site of challenge in all the groups. The most striking result was the lack of pathogenicity of the attenuated parasite, which persisted in infected animals for up to three months, but were incapable of causing disease under the conditions employed. We concluded that both vaccine protocols used in this study are safe in primates, but require further improvement for vaccine application.

Saved in:
Bibliographic Details
Main Authors: Amaral,VF, Teva,A, Oliveira-Neto,MP, Silva,AJ, Pereira,MS, Cupolillo,E, Porrozzi,R, Coutinho,SG, Pirmez,C, Beverley,SM, Grimaldi Jr,G
Format: Digital revista
Language:English
Published: Instituto Oswaldo Cruz, Ministério da Saúde 2002
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762002000700019
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0074-02762002000700019
record_format ojs
spelling oai:scielo:S0074-027620020007000192002-12-04Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human diseaseAmaral,VFTeva,AOliveira-Neto,MPSilva,AJPereira,MSCupolillo,EPorrozzi,RCoutinho,SGPirmez,CBeverley,SMGrimaldi Jr,G Leishmania (L.) major rhesus macaques (Macaca mulatta) vaccination attenuated and killed promastigotes bacillus Calmete-Guerin (BCG) We have compared the efficacy of two Leishmania (Leishmania) major vaccines, one genetically attenuated (DHFR-TS deficient organisms), the other inactivated [autoclaved promastigotes (ALM) with bacillus Calmete-Guérin (BCG)], in protecting rhesus macaques (Macaca mulatta) against infection with virulent L. (L.) major. Positive antigen-specific recall proliferative response was observed in vaccinees (79% in attenuated parasite-vaccinated monkeys, versus 75% in ALM-plus-BCG-vaccinated animals), although none of these animals exhibited either augmented in vitro gamma interferon (IFN-<FONT FACE=Symbol>g</font>) production or positive delayed-type hypersensitivity (DTH) response to the leishmanin skin test prior to the challenge. Following challenge, there were significant differences in blastogenic responses (p < 0.05) between attenuated-vaccinated monkeys and naïve controls. In both vaccinated groups very low levels of antibody were found before challenge, which increased after infective challenge. Protective immunity did not follow vaccination, in that monkeys exhibited skin lesion at the site of challenge in all the groups. The most striking result was the lack of pathogenicity of the attenuated parasite, which persisted in infected animals for up to three months, but were incapable of causing disease under the conditions employed. We concluded that both vaccine protocols used in this study are safe in primates, but require further improvement for vaccine application.info:eu-repo/semantics/openAccessInstituto Oswaldo Cruz, Ministério da SaúdeMemórias do Instituto Oswaldo Cruz v.97 n.7 20022002-10-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762002000700019en10.1590/S0074-02762002000700019
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Amaral,VF
Teva,A
Oliveira-Neto,MP
Silva,AJ
Pereira,MS
Cupolillo,E
Porrozzi,R
Coutinho,SG
Pirmez,C
Beverley,SM
Grimaldi Jr,G
spellingShingle Amaral,VF
Teva,A
Oliveira-Neto,MP
Silva,AJ
Pereira,MS
Cupolillo,E
Porrozzi,R
Coutinho,SG
Pirmez,C
Beverley,SM
Grimaldi Jr,G
Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease
author_facet Amaral,VF
Teva,A
Oliveira-Neto,MP
Silva,AJ
Pereira,MS
Cupolillo,E
Porrozzi,R
Coutinho,SG
Pirmez,C
Beverley,SM
Grimaldi Jr,G
author_sort Amaral,VF
title Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease
title_short Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease
title_full Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease
title_fullStr Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease
title_full_unstemmed Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease
title_sort study of the safety, immunogenicity and efficacy of attenuated and killed leishmania (leishmania) major vaccines in a rhesus monkey (macaca mulatta) model of the human disease
description We have compared the efficacy of two Leishmania (Leishmania) major vaccines, one genetically attenuated (DHFR-TS deficient organisms), the other inactivated [autoclaved promastigotes (ALM) with bacillus Calmete-Guérin (BCG)], in protecting rhesus macaques (Macaca mulatta) against infection with virulent L. (L.) major. Positive antigen-specific recall proliferative response was observed in vaccinees (79% in attenuated parasite-vaccinated monkeys, versus 75% in ALM-plus-BCG-vaccinated animals), although none of these animals exhibited either augmented in vitro gamma interferon (IFN-<FONT FACE=Symbol>g</font>) production or positive delayed-type hypersensitivity (DTH) response to the leishmanin skin test prior to the challenge. Following challenge, there were significant differences in blastogenic responses (p < 0.05) between attenuated-vaccinated monkeys and naïve controls. In both vaccinated groups very low levels of antibody were found before challenge, which increased after infective challenge. Protective immunity did not follow vaccination, in that monkeys exhibited skin lesion at the site of challenge in all the groups. The most striking result was the lack of pathogenicity of the attenuated parasite, which persisted in infected animals for up to three months, but were incapable of causing disease under the conditions employed. We concluded that both vaccine protocols used in this study are safe in primates, but require further improvement for vaccine application.
publisher Instituto Oswaldo Cruz, Ministério da Saúde
publishDate 2002
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762002000700019
work_keys_str_mv AT amaralvf studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease
AT tevaa studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease
AT oliveiranetomp studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease
AT silvaaj studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease
AT pereirams studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease
AT cupolilloe studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease
AT porrozzir studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease
AT coutinhosg studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease
AT pirmezc studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease
AT beverleysm studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease
AT grimaldijrg studyofthesafetyimmunogenicityandefficacyofattenuatedandkilledleishmanialeishmaniamajorvaccinesinarhesusmonkeymacacamulattamodelofthehumandisease
_version_ 1756383432374484992